SpringWorks Therapeutics Inc
SWTX
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
182.1% downsideOvervalued by 182.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.54 Billion |
|---|---|
| Enterprise Value | $3.50 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.48 |
| Beta | 0.7 |
| Outstanding Shares | 74,885,348 |
Return
| Return on Equity | -60.84% |
|---|---|
| Return on Assets | -50.25% |
| Return on Invested Capital | -62.57% |
Valuation & Multiples
| P/E Ratio | -21.93 |
|---|---|
| PEG | 456.42 |
| Price to Sales | 23.5 |
| Price to Book Ratio | 9.4 |
| Enterprise Value to Revenue | 15.93 |
| Enterprise Value to EBIT | -13.22 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0895▼ 35.07% |
|---|---|
| Total Calls | 9,323,649▲ 61.25% |
| Total Puts | 834,300▼ 67.22% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 100.34%▲ 1.92% |
|---|---|
| Total Invested | $3.53B▲ 8.48% |
| Investors Holding | 248▼ 103.00% |
ESG Score
No data
About SpringWorks Therapeutics Inc
Relevant Senate Committees
Controls tax policy and entitlement spending (e.g., Medicare drug pricing), which directly impact profitability, market access, and overall valuation for biological product manufacturers.
Directly regulates the FDA, which is the primary regulatory body for drug approval and oversight, directly impacting the core business of biological product manufacturers.
Critical for intellectual property rights (patents) and antitrust enforcement, which are foundational to the biotech and pharmaceutical industries for protecting innovation and market competition.